Voon, V
B., Porsbjerg, C., & Scheibye-Knudsen, M
Ramos-Gomez M, Kwak MK, Dolan PM, Itoh K, Yamamoto M, Talalay P, et al
In the REDEFINE 1 phase 3 trial (NCT05567796), which enrolled adults with overweight or obesity (BMI 27 kg/m) and at least 1 weight-related comorbidity but without type 2 diabetes, participants receiving CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg) achieved a mean body weight reduction of 22.7% from baseline after 68 weeks among adherent participants, compared with approximately 3% in the placebo group.5 These results establish CagriSema as one of the most potent antiobesity therapies investigated to date
Cardiovascular Diabetology, 35(4), 178-185
Additionally, athletes and fitness enthusiasts often incorporate IV Therapy into their recovery routines to support muscle recovery and performance